Pfizer’s revenue from Paxlovid and Comirnaty fell to $1,257 million in the third quarter of 2026 from $2,376 million a year earlier, according to the product table in its results release on 3 November. Its other products brought in $15,326 million, up from $14,278 million.
By our arithmetic, the COVID-19 products lost $1.12 billion and everything else gained $1.05 billion, so total revenue was nearly unchanged at $16.6 billion. The two COVID products made up 7.6% of revenue, against 14.3% a year earlier.
Business Pill · Operating Leverage
A short explainer on operating leverage: why profit can grow faster than sales. It teaches the general idea only and does not discuss Pfizer.
The key insight: By our arithmetic, Pfizer’s COVID products shrank to 7.6% of revenue from 14.3% in a year, and the $1.05 billion gained by everything else covered almost all of the $1.12 billion they lost.
Revenue was $16,583 million, against $16,654 million, which Pfizer describes as relatively flat; the release puts the operational decrease at $57 million. Excluding Comirnaty and Paxlovid, it says revenue grew 7% operationally, and revenue from what it calls launched and acquired products grew 32% operationally.
Reported diluted earnings per share were $0.56, against $0.62, and adjusted diluted EPS was $0.87, unchanged. Wall St Engine cited consensus estimates of $15.87 billion for revenue and $0.73 for adjusted EPS.
Chief financial officer Cecile Guegan said in the release: “This quarter, our non-COVID products delivered strong 7% operational revenuegrowth, and I’m particularly pleased with the 32% year-over-year operational revenuegrowth from our launched and acquired products.”
Pfizer’s third-quarter revenue from Paxlovid and Comirnaty versus all other products, 2025 and 2026, from the productrevenue table in its Q3 2026 release. The split is our arithmetic on reported figures. Chart: FourWeekMBA.
Wall St Engine posted its third-quarter 2026 earnings highlights card for Pfizer at 11:46 UTC on 3 November, listing revenue of $16.6 billion against an estimate of $15.87 billion, adjusted EPS of $0.87 against $0.73 and the raised full-year guidance. The figures in this piece come from Pfizer’s own release and 10-Q; the post is cited only for the consensus estimates.
Where the Gains and Losses Came From
The release lists the largest operational increases: Eliquis up $513 million, or 25%, Padcev up $255 million, the Vyndaqel family up $193 million, Nurtec ODT/Vydura up $135 million and Lorbrena up $114 million. For Eliquis it cites higher net price in the U.S., including lower rebates and channel mix, and higher demand globally.
On the other side, Paxlovid fell $771 million, or 63%, operationally, which the release attributes mainly to lower COVID-19 infections. Comirnaty fell $339 million, or 29%, and the Prevnar family fell $180 million, or 10%.
By our arithmetic, Eliquis’s $513 million operational gain alone was almost half the size of the $1.05 billion reported gain from products outside COVID.
What the Raised Guidance Implies for the Fourth Quarter
Pfizer raised its 2026 revenue guidance to $62.0 billion to $64.0 billion, from $60.5 billion to $62.5 billion, and its adjusted diluted EPS guidance to $2.95 to $3.05, from $2.80 to $3.00. The EPS range includes a one-time $650 million acquired in-process R&D charge for the Innovent Biologics deal, which the release puts at about $0.10 a share.
Revenue for the first nine months was $46,067 million. By our arithmetic, the new range implies fourth-quarter revenue of $15.9 billion to $17.9 billion, or $16.9 billion at the midpoint. SEC filings put fourth-quarter 2025 revenue at $17.6 billion, so the midpoint is about 3.6% lower and the top of the range about 2% higher.
Nine-month adjusted EPS was $2.39, so the range implies fourth-quarter adjusted EPS of $0.56 to $0.66, by our arithmetic.
The AI and Cost Lever
Pfizer’s 10-Q, also filed on 3 November, describes the cost realignment program it began in late 2023. It says that in the second quarter of 2025 Pfizer found further savings in selling, informational and administrative costs, “driven in large part by enhanced digital enablement, including automation and AI, and simplification of business processes.”
At its second-quarter results on 4 August, Pfizer announced $1.0 billion of additional net cost savings from “further productivity enhancements from technology and simplification efforts”, to be realized from 2027 through 2029 at one-time costs of about $2.0 billion. With that tranche, the 10-Q says Pfizer now expects total net cost savings of about $6.7 billion from the program through 2029. It puts the costs of all components at about $7.3 billion, of which $5.7 billion had been incurred from the start of the program through 27 September.
The 10-Q also lists among its forward-looking statements “our expectations regarding AI and our ability to successfully integrate and scale our AI initiatives.” The release says guidance reflects progress with ongoing cost improvement initiatives.
Patents and Capital
The 10-Q says Pfizer expects a significant reduction of revenue from patent-based or regulatory exclusivity expiries from 2026 through 2030, and an unfavorable revenue impact from those expiries of about $1.1 billion in 2026.
In the first nine months Pfizer invested $8.3 billion in internal research and development and paid $7.3 billion in dividends, or $1.29 a share. The release says no share repurchases have been completed in 2026, that $3.3 billion of authorization remains, and that guidance does not anticipate any buybacks this year.
What the Risk Factors Say
The 10-Q lists no new risk factors. Its risk factor section refers readers to the 2025 annual report and to the operating-environment sections of the quarterly filing.
The Structural Read
As we read the release, Pfizer’s flat headline revenue hides two opposite moves of about the same size: COVID products fell by almost half while Eliquis, Padcev and other brands grew.
As we read the 10-Q, AI shows up at Pfizer as a cost lever rather than a revenue line: the filing names automation and AI among the drivers of savings in selling, informational and administrative costs.
Albert Bourla, Pfizer chairman and chief executive, Q3 2026 release
“Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing our strategy for creating long-term shareholder value”
Three Implications
FOR THE REVENUE MIX Paxlovid and Comirnaty brought in $1,257 million in the quarter, against $15,326 million from all other products, per the release’s product table and our arithmetic.
FOR THE FOURTH QUARTER Full-year guidance of $62.0 billion to $64.0 billion implies fourth-quarter revenue of $15.9 billion to $17.9 billion, against $17.6 billion a year earlier, by our arithmetic.
FOR COSTS Pfizer announced $1.0 billion of additional net savings in August from technology and simplification, at one-time costs of about $2.0 billion, per its second-quarter release.
The framework argues: “The constraint is access to systems, management expectations, workforce skill, and review processes โ the complements, not the engine.”
As we read it, Pfizer’s filing describes its AI-linked savings in similar terms: digital enablement paired with simplification of business processes. The framework is the owner’s argument and does not discuss Pfizer.
What Is Not Established
The release does not give a fourth-quarter forecast; the implied range is our arithmetic on full-year guidance and reported nine-month results, and does not separate COVID products from the rest. The COVID and non-COVID split uses reported figures, which include currency effects, while Pfizer’s own growth rates are operational.
Pfizer does not say how much of its cost savings come from AI specifically; the 10-Q names AI among several sources of the 2025 productivity phase, and the August tranche is described as technology and simplification. This piece does not draw on the earnings call or assess any clinical data.
This Week In The AI Supercycle
Anthropic’s Reality Check, The Capital Squeeze, & The New World Order
This week’s issue: for two years the AI build-out was priced as a growthstory. This week it started being priced as a credit story.
Pfizer’s third quarter shows a swap inside an unchanged total: by our arithmetic, Paxlovid and Comirnaty lost $1.12 billion while other products added $1.05 billion, and COVID fell to 7.6% of revenue from 14.3%. The raised guidance implies fourth-quarter revenue of $15.9 billion to $17.9 billion, against $17.6 billion a year earlier.
95,000+ executives read Business Engineer for the AI strategy frameworks cited by ChatGPT, Claude, and Perplexity.
A note on sourcing. Figures and quotes come from Pfizer’s third-quarter 2026 results release (Form 8-K Exhibit 99) and Form 10-Q, both filed with the SEC on 3 November 2026, its second-quarter release of 4 August 2026, and SEC XBRL revenue data. Consensus estimates are as cited by Wall St Engine on X. The COVID and non-COVID split, shares and implied fourth-quarter ranges are our arithmetic. This piece makes no claim about the safety or efficacy of any medicine. We did not contact Pfizer.
Gennaro Cuofano is a CRO and tech executive who has worked in AI since late 2015, starting with bringing NLP, natural-language generation, voice and chatbot products to the marketing industry. His background is in law and finance: he holds a Master's degree in Law and an International MBA with an emphasis on corporate finance (LUISS Business School and the University of San Diego, 2012), and worked as a financial analyst at a real-estate investment firm in San Diego and as an assistant controller. His work focuses on business model strategy, business engineering and, more broadly, structural analysis: how companies make money, read from their own filings. He created FourWeekMBA and leads research there and at The Business Engineer, his newsletter on AI and business strategy, with over 95,000 subscribers and more than 1,000 published analyses. His writing has also appeared on Entrepreneur (for example, How to Digitize a Family Business in Europe) and HackerNoon. Find him on LinkedIn and Substack. See how we source.
